HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Partner Therapeutics secures FDA approval for Bizengri

Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring an NRG1 gene fusion and who have progressed on or after prior systemic therapy.

By Pharmaceutical Technology · May 12, 2026 · via Pharmaceutical Technology
Partner Therapeutics secures FDA approval for Bizengri

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
pipelineformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
PipelineFierceBiotech ↗
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, e…
May 12, 2026
BMS’ Sotyktu secures EC approval for psoriatic arthritis
PipelinePharmaceutical Technology ↗
BMS’ Sotyktu secures EC approval for psoriatic arthritis
BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …
May 11, 2026
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
PipelineFiercePharma ↗
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
May 10, 2026